Conditioned medium from amniotic fluid mesenchymal stem cells could modulate Alzheimer's disease-like changes in human neuroblastoma cell line SY-SY5Y in a paracrine manner.

Autor: Hasanpour M; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Basic Medical Sciences, Khoy University of Medical Sciences, Khoy, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran., Rahbarghazi R; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran., Nourazarian A; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Basic Medical Sciences, Khoy University of Medical Sciences, Khoy, Iran. Electronic address: alinour65@gmail.com., Khaki-Khatibi F; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Avci ÇB; Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey., Hassanpour M; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Talebi M; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Taghavi H; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Salimi L; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Jazyk: angličtina
Zdroj: Tissue & cell [Tissue Cell] 2022 Jun; Vol. 76, pp. 101808. Date of Electronic Publication: 2022 May 04.
DOI: 10.1016/j.tice.2022.101808
Abstrakt: Background: Alzheimer's disease is usually diagnosed by significant extracellular deposition of beta-amyloid and intracellular neurofibrillary tangle formation. Here, we investigated the paracrine effect of amniotic fluid-derived mesenchymal stem cells on AD changes in human SH-SY5Y cells.
Methods: SH-SY5Y cells were divided into five groups: Control, 0.1 µg/ml LPS, 10 µg/ml LPS, 0.1 µg/ml LPS + conditioned medium, and 10 µg/ml LPS + conditioned medium. Cells were incubated with 0.1% and 10 µg/ml LPS for 48 h, followed by incubation with the conditioned medium of amniotic fluid-derived mesenchymal stem cells for the next 24 h. Beta-amyloid plaques were monitored by Congo-red staining. Survival and apoptosis were assessed by the MTT assay and flow cytometric analysis of Annexin-V. ELISA was used to measure the levels of neprilysin, angiotensin-converting enzyme, and Matrix Metalloproteinase-9. A PCR array was used to measure the expression of genes involved in neurogenesis.
Results: Bright-field imaging showed beta-amyloid plaques in the group treated with 10 µg/ml LPS. We found minimal effects in groups receiving 0.1 µg/ml LPS. The data showed that the reduction in the levels of neprilysin, angiotensin-converting enzyme, and Matrix Metalloproteinase-9 in the LPS-treated cells was attenuated after incubation with the stem cell secretome (p < 0.05). Amniotic fluid stem cell secretome increased the viability of LPS-treated SH-SY5Y cells (p 0.05) and was associated with a decrease in apoptotic changes (p < 0.05). We found the modulation of several genes involved in neurogenesis in the 10 µg/ml LPS + conditioned medium group compared to cells treated with 10 µg/ml LPS alone.
Conclusion: Amniotic fluid stem cell secretion reduces AD-like pathologies in the human neuronal lineage.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: